<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691730</url>
  </required_header>
  <id_info>
    <org_study_id>PHL-064</org_study_id>
    <secondary_id>NCI-2009-00277</secondary_id>
    <secondary_id>PMH-PHL-064</secondary_id>
    <secondary_id>CDR0000588665</secondary_id>
    <nct_id>NCT00691730</nct_id>
  </id_info>
  <brief_title>Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer</brief_title>
  <acronym>NCI 8076</acronym>
  <official_title>The Role of VEGF-A Signaling in Maintenance of the Glomerular Filtration Barrier and Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is looking at kidney and blood pressure changes in patients receiving&#xD;
      bevacizumab, aflibercept, sunitinib, or cediranib for cancer. Studying samples of blood and&#xD;
      urine from patients with cancer in the laboratory may help doctors learn more about changes&#xD;
      that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict&#xD;
      how patients will respond to treatment with an antiangiogenic drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. To study the renal and blood pressure changes in patients treated with bevacizumab,&#xD;
      aflibercept, sunitinib malate, or cediranib for their cancer.&#xD;
&#xD;
      II. To determine the physiological mechanisms behind proteinuria and hypertension induced by&#xD;
      antiangiogenic therapies (i.e., rarefaction; imbalance in eNOS, prostacyclin [PGI_2],&#xD;
      prostaglandin E2 [PGE_2], and thromboxane A2 [TXA2]; renin/aldosterone; or renovascular&#xD;
      hypertension).&#xD;
&#xD;
      III. To determine whether soluble factors (like tyrosine kinase 1 [sFlt1], bFGF, and VEGF)&#xD;
      and steady state drug concentration are predictive of the development of&#xD;
      proteinuria/hypertension.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients undergo blood and urine sample collection periodically. Urine samples are assessed&#xD;
      for PGI2 and TXA2 levels using validated ELISA methods. Urine is also assessed for protein&#xD;
      and creatinine levels, microalbumin, osmolality, and electrolytes. Blood samples are assessed&#xD;
      for pharmacokinetics and sFlt1, VEGF, and bFGF levels by validated ELISA methods. Blood&#xD;
      samples are also assessed for steady state drug concentration, renin, and aldosterone levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2008</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Renal and blood pressure changes</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiological mechanism behind proteinuria and hypertension induced by antiangiogenic therapies</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Predictive value of soluble factors in the development of proteinuria or hypertension</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Predictive value of steady state drug concentrations in the development of proteinuria or hypertension</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">52</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Only sample collection, no other intervention - Correlative studies</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are going to start treatment with bevacizumab, VEGF Trap, sunitinib or&#xD;
        AZD2171.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Planning to start treatment with one of the following antiangiogenic drugs as single&#xD;
             agents or in combination with chemotherapy for their cancer:&#xD;
&#xD;
               -  Cediranib (AZD2171 )&#xD;
&#xD;
               -  Bevacizumab (Avastin)&#xD;
&#xD;
               -  Sunitinib (Sutent)&#xD;
&#xD;
               -  Aflibercept (VEGF Trap)&#xD;
&#xD;
          -  Urinalysis negative for protein OR 24-hour urine for protein &lt; 500 mg&#xD;
&#xD;
          -  Prior chemotherapy within the past 12 months allowed&#xD;
&#xD;
          -  More than 12 months since prior antiangiogenic drugs, including monoclonal antibodies&#xD;
             that bind to VEGF or tyrosine kinase inhibitors that block VEGFR2&#xD;
&#xD;
          -  At least 6 weeks since prior and no concurrent aldosterone receptor antagonists (e.g.,&#xD;
             spironolactone [aldactone] or eplerenone)&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Moore</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network-Princess Margaret Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 4, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

